European Medicines Agency to review ozanimod for the treatment of ulcerative colitis

The market authorisation application was based on results from True North, a placebo-controlled Phase 3 trial evaluating ozanimod as an induction and maintenance therapy in adults with moderately to severely active ulcerative colitis.

Biospace Inc.